|
1) |
Oesterling JE. Prostate specific antigen:a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol. 1991;145:907-23. |
2) |
Gretzer MB, Partin AW. PSA markers in prostate cancer detection. Urol Clin North Am. 2003;30:677-86. |
3) |
Okihara K, Cheli CD, Partin AW, et al. Comparative analysis of complexed prostate specific antigen, free prostate specific antigen and their ratio in detecting prostate cancer. J Urol. 2002;167:2017-23. |
4) |
)Keetch DW, Catalona WJ, Smith DS. Serial prostate biopsies in men with persistently elevated serum prostate specific antigen values. J Urol. 1994;151:1571-4. |
5) |
Roerhborn CG, Pickers GJ, Sanders JS. Diagnostic yield of repeated transrectal ultrasound-guided biopsies stratified by specific histopathologic diagnosis and prostate specific antigen levels. Urology. 1996;47:347-52. |
6) |
Singh H, Canto EL, Shariat SF, et al. Predictors of prostate cancer after initial negative systematic 12 core biopsy. J Urol. 2004;171:1850-4. |
7) |
Park SJ, Miyake H, Hara I, et al. Predictors of prostate cancer on repeat transrectal ultrasound-guided systematic prostate biopsy. Int J Urol. 2003;10:68-71. |
8) |
Bill-Axelson A, Holmberg L, Norlen B, et al. No increased prostate cancer incidence after negative transrectal ultrasound guided multiple biopsies in men with increased prostate specific antigen and/or abnormal digital rectal examination. J Urol. 2003;170:1180-3. |
9) |
Catalona WJ, Partin AW, Slawin KM, et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease:a prospective multicenter clinical trial. JAMA. 1998;279:1542-7. |